Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Event: January 12, 2009
Context: The filing announces full-year earnings per share (EPS) guidance for 2009 and confirms previously issued 2008 EPS guidance.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification of guidance announcements rather than a detailed financial statement.
Material Changes and Guidance
- 2009 Outlook: Full-year earnings per share guidance for 2009 was announced.
- 2008 Confirmation: Previously issued 2008 earnings per share guidance was confirmed.
- Non-GAAP Measures: Management utilizes a non-GAAP measure of diluted earnings per common share, excluding specified items such as acquisition-related costs, cost reduction initiatives, acquired in-process research and development, and gains/losses on certain investments.
Management Commentary and Risks
Management states that the non-GAAP measure provides useful information for evaluating ongoing business performance and is used internally to monitor operations. However, the filing includes a caution that this non-GAAP measure should be considered in addition to, and not as a substitute for, GAAP financial measures.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for the specific numerical values of the 2009 and 2008 EPS guidance.
- Verify the reconciliation between the reported non-GAAP diluted earnings per share and the GAAP equivalent.
- Assess the impact of excluded items (e.g., acquisition costs, R&D) on the company's reported profitability.